NCT05601063

Brief Summary

Cross-sectional observational study of the relationship between speech patterns and psychiatric symptoms and disorders.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
255

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 1, 2022

Completed
Last Updated

November 1, 2022

Status Verified

October 1, 2022

Enrollment Period

1.9 years

First QC Date

October 25, 2022

Last Update Submit

October 29, 2022

Conditions

Keywords

Psychiatrylanguagenatural language processingdigital health

Outcome Measures

Primary Outcomes (1)

  • Speech features from the Winterlight Speech Assessment

    Acoustic and linguistic measures of speech computed based on performance on the Winterlight Speech Assessment

    Baseline

Secondary Outcomes (5)

  • Brief Symptom Inventory

    Baseline

  • Patient Health Questionnaire - 9

    Baseline

  • Generalized Anxiety Disorder - 7

    Baseline

  • Prodromal Questionnaire - Brief

    Baseline

  • Scale for the Assessment of Thought Language and Communication

    Baseline

Study Arms (2)

Psychiatric patient group

Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable. * Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder * Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder * (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder * Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder * Personality disorder - borderline personality disorder * Attention-Deficit Hyperactivity Disorder

Behavioral: Winterlight Speech Assessment

Healthy controls

Healthy comparison subjects with no known psychiatric diagnosis

Behavioral: Winterlight Speech Assessment

Interventions

Digital assessment of speech and language abilities

Healthy controlsPsychiatric patient group

Eligibility Criteria

Age14 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients whose treatment team believes they would be appropriate for a research study will be approached by research staff and the research project will be explained to them in detail. Inpatients will be approached during their admission and after initial stabilization. Outpatients will be approached before or after their scheduled appointments. Educational seminars regarding this study may be held to inform clinicians and staff of our goals and protocol. Potential participants will be made aware that declining participation will not affect their care. Informed consent will be obtained from all those interested in participating in the study.

You may qualify if:

  • Speaks with conversational proficiency with conversational proficiency
  • Current diagnosis in the medical chart of any of the following. The patient may be in partial but not full remission. Comorbidity among these disorders and other unlisted disorders is expected and allowable.
  • Schizophrenia-spectrum disorder - schizophrenia, schizophreniform, schizoaffective disorder, delusional disorder, brief psychotic disorder, or unspecified psychotic disorder
  • Bipolar spectrum disorder - bipolar I or II disorder, cyclothymia, unspecified or other specified bipolar disorder
  • (Unipolar) Depressive disorder - major depressive disorder, dysthymia, unspecified and other specified depressive disorder
  • Anxiety disorder - obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, post-traumatic stress disorder
  • Personality disorder - borderline personality disorder
  • Attention-Deficit Hyperactivity Disorder
  • Healthy comparison subjects
  • Age 14 - 50 years
  • Has capacity and willing to sign informed consent; if minor, parent is willing to give consent and child is willing to give assent.
  • Screening will not include a pregnancy test. Pregnant women will not be screened out of the study because the study procedures are of very low risk overall, and pregnancy does not place the participant or the fetus at any significant risk.
  • Minors will be included in the study because diagnostic ambiguity is prevalent before the age of 18 and this patient group is particularly in need of accurate prognosis and treatment. Therefore, it is of vital importance that the conclusions of the study be applicable to minors and that they be included among the participants.

You may not qualify if:

  • Participants with substance-induced disorders or disorders secondary to a general medical condition will not be included as underlying brain changes may be different from "primary" psychiatric disorders.
  • Disorders affecting speech or language, such as aphasia, intellectual disability (IQ\<70), or language disorder, or movement disorders affecting speech like tardive dyskinesia, or physical impairments causing significant distortions to speech
  • Serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain and/or language, including but not limited to: neurodegenerative disorders, traumatic brain injury with active symptoms, autism spectrum disorder, encephalitis, epilepsy
  • Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zucker Hillside Hospital

Glen Oaks, New York, 11004, United States

Location

MeSH Terms

Conditions

Schizophrenia Spectrum and Other Psychotic DisordersBipolar and Related DisordersDepressive DisorderAnxiety DisordersPersonality DisordersAttention Deficit Disorder with HyperactivityLanguage

Condition Hierarchy (Ancestors)

Mental DisordersMood DisordersAttention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersCommunicationBehavior

Study Officials

  • Sunny X Tang, MD

    Northwell Health, The Feinstein Institutes of Medical Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 25, 2022

First Posted

November 1, 2022

Study Start

October 1, 2020

Primary Completion

September 1, 2022

Study Completion

September 1, 2022

Last Updated

November 1, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations